RNAZ Transcode Therapeutics, Inc.
Price Chart
Executive Summary
Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum stockholders' equity requirement, reporting equity of only $1.25M as of March 31, 2026. The company is soliciting shareholder approval to convert Series A and B preferred stock into common stock to boost equity and regain compliance, but failure could lead to redemption demands and potential delisting.
Actionable Insight
Monitor the upcoming shareholder vote on preferred stock conversion; approval would restore equity compliance and remove near-term delisting risk, while denial could trigger redemption demands and accelerate delisting. Given the $6M market cap, any adverse development could be severely dilutive or wipe out equity.
Key Facts
- Received Nasdaq deficiency letter on May 19, 2026, for non-compliance with Listing Rule 5550(b)(1) (minimum stockholders' equity of $2.5M)
- Stockholders' equity as of March 31, 2026, was $1,251,427, well below the $2.5M threshold
- Company must submit a compliance plan by July 3, 2026, and may get up to 180 days extension
- Seeking shareholder approval to convert Series A and B preferred stock into common stock to reclassify as equity and regain compliance
- If approval not obtained by Dec 31, 2026, preferred holders can demand redemption at fair value, creating cash outflow risk
Financial Impact
Stockholders' equity deficiency of $1,248,573 relative to $2.5M requirement; potential cash redemption of Series A preferred if conversion not approved
Risk Factors
- Shareholder vote may fail to approve conversion, leading to preferred redemption demands and potential cash crunch
- Nasdaq may reject the compliance plan or fail to grant an extension, resulting in delisting
- Even if compliance plan is accepted, the company may not regain compliance within extension period
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-065966 |
| Document: 0001104659-26-065966-index-headers.html | 0001104659-26-065966 |
| Document: 0001104659-26-065966-index.html | 0001104659-26-065966 |
| Document: 0001104659-26-065966.txt | 0001104659-26-065966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
10d ago
|
8-K
| $5.04 $5.84 | ▲ +15.87% | ▲ +15.47% | $5.33 (+5.75%) |
|
May 26, 2026
18d ago
|
DEFA14A
| $5.39 $5.09 | ▲ +5.57% | ▲ +5.58% | $5.33 (+1.11%) |
|
Apr 30, 2026
6w ago
|
S-3
| $7.83 $7.74 | ▲ +1.15% | ▲ +0.81% | $5.33 (+31.93%) |
|
Apr 7, 2026
9w ago
|
8-K
| $8.70 $8.36 | ▲ +3.91% | ▲ +6.45% | $5.33 (+38.74%) |
|
Mar 3, 2026
14w ago
|
DEFA14A
| $9.84 $9.33 | ▼ −5.18% | ▼ −4.61% | $5.33 (−45.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access